WA
SYRE icon

Waverly Advisors’s Spyre Therapeutics SYRE Stock Holding History

Waverly Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Sell
25,512
-454
-2% -$33.1K 0.01% 663
2026
Q1 		$1.31M Buy
25,966
+12
+0% +$452 0.01% 746
2025
Q4 		$850K Buy
25,954
+1
+0% +$26 0.01% 810
2025
Q3 		$435K Buy
25,953
+6,500
+33% +$106K ﹤0.01% 901
2025
Q2 		$291K Buy
19,453
+23
+0.1% +$340 ﹤0.01% 979
2025
Q1 		$314K Buy
+19,430
New +$404K ﹤0.01% 908

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Waverly Advisors's SYRE Position: Q2 2026 in Review

Waverly Advisors reduced its Spyre Therapeutics (SYRE) stake by 1.7% in Q2 2026, selling an estimated $33.1K and leaving 25,512 shares worth $2.26M. The position accounts for 0.01% of the portfolio, ranked #663.

Waverly Advisors first reported a position in SYRE in Q1 2025 and has held it in 6 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Waverly Advisors held 25,512 shares of Spyre Therapeutics worth $2.26M as of Q2 2026.
  • Waverly Advisors sold 454 Spyre Therapeutics shares in Q2 2026, an estimated $33.1K.
  • Spyre Therapeutics made up 0.01% of Waverly Advisors's portfolio in Q2 2026, its #663 holding.
  • Waverly Advisors first reported a position in Spyre Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Waverly Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.